Prospective Risk Stratification for Lupus Nephritis in SLE: Retrospective Validation of a Multi-Layer Computational Engine

Lupus nephritis (LN) is a major cause of renal morbidity in SLE patients. To address the need for earlier and more individualized risk identification, we developed a computational engine incorporating longitudinal phenotype trajectories, treatment burden, and traditional biomarkers into a unified risk-scoring framework. The engine was retrospectively validated across a synthetic longitudinal cohort of 377 SLE patients, outputting a continuous composite score (0–100) and a four-tier risk classification: Low / Moderate / High / Critical. At the Moderate+ screening threshold, the engine achieved 100% sensitivity and 100% NPV within 90 days of confirmed LN diagnosis — meaning zero missed progressors. These findings suggest that this computational engine can identify patients approaching lupus nephritis up to 90 days before diagnosis, giving clinicians a critical window to intervene early, triage high-risk patients, and initiate nephrology referrals sooner.

Read More
Clinical Validation of a Refined Lupus Disease Activity Index Informed by Immune Mediators that Characterizes Clinical and Serological Disease Activity In Systemic Lupus Erythematosus

This study sought to identify an optimal panel of immune mediators to distinguish SLE patients with active versus low/quiescent disease and refine the Lupus Disease Activity Index (L-DAI). Using plasma immune mediators and serum autoantibody specificities from classified SLE patients, we applied random forest modeling to determine the most informative analytes. A refined panel of 9 immune mediators, including IFN-α, significantly differentiated SLE patients with active versus low disease activity, with strong correlation to clinical disease activity scores (hSLEDAI). The L-DAI demonstrated a large effect size and strong discriminatory performance (AUC=0.795). The findings support the use of a sensitive, objective biomarker surrogate for clinical disease activity in SLE, with the potential to improve disease management and prevent organ damage.

Read More
Dysregulated soluble immune mediators and lupus-associated autoantibody specificities inform the development of immune indexes that characterise classified SLE transition and SLE disease activity

Systemic lupus erythematosus (SLE) is a complex autoimmune disease. Significant morbidity and early mortality necessitate early intervention. This study harnessed SLE-associated immune dysregulation to create a Lupus Classification Risk Index (LCRII) and Lupus Disease Activity Immune Index (LDAII) that identified individuals at risk for SLE classification and disease activity.

Read More
Biomarker panel increases accuracy for identification of an MS relapse beyond sNfL

This study aimed to identify a panel of biomarkers that would increase the precision of distinguishing patients in relapse compared to sNfL alone. Findings  identified four blood protein including sNFL,  uPA, hK8 and DSG3 that accurately distinguished relapse from remission in RRMS patients, providing an improved biomaker panel for monitioring disease activity beyond traditional measures.

Read More
Cytokine profiles show heterogeneity of interferon-b response in multiple sclerosis patients

This study evaluated serum cytokine profiles for their utility to determine the heterogeneous responses to interferon (IFN)-β treatment in patients with multiple sclerosis (MS). Findings revealed that six cytokine-based subgroups with varied IFN-B  treatment responses. Some subsets showed poor outcomes, while others had reduced  relapses, highlighting immune heterogeneity linked to therapy effectiveness. 

Read More
Medical Record Natural Language Processing and Patient Biometric and Self-Reported Measures Inform an Artificial Intelligence Augmented Remote Care Management Strategy for Lupus Patients

This study combined natural language processing of medical records with patient biometric and self-reported data. Strong correlations identified 24 metrics predicting physician assessments, supporting AI-augmented remote lupus management strategies.

Read More
Expediting Systemic Lupus Erythematosus Classification of at-Risk Individuals Using Novel Technology: Outcomes of a Pilot Study

This study used a virtual/digital program to recruit at-risk individuals via online screening and sequential telehealth evaluations, classifying 18% with SLE in a mean of 371 days—shortening typical diagnosis time from 5-7 years—demonstrating potential for remote, accurate lupus assessment.

Read More
Tracking of Systemic Lupus Erythematosus (SLE) Longitudinally Using Biosensor and Patient-Reported Data: A Report on the Fully Decentralized Mobile Study to Measure and Predict Lupus Disease Activity Using Digital Signals-The OASIS Study

This decentralized study used machine learning to assess patient-reported outcomes, quality-of-life measures, and smartwatch biometric data from SLE patients. Models achieved significant predictive accuracy for disease flares, supporting proactive clinical screening.

Read More
Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification

This study shows immune changes appear years before lupus is diagnosed: “type II interferon” and certain blood signals rise first, autoantibodies build next, and “type I interferon” spikes closest to diagnosis; combining these markers accurately flags high-risk individuals for earlier evaluation.

Read More
Discerning risk of disease transition in relatives of systemic lupus erythematosus patients utilizing soluble mediators and clinical features

This study followed relatives of people with lupus and found those who later developed the disease already had higher “inflammation” signals in blood and lower “calming” signals; two markers, SCF (higher) and TGF-β (lower), best predicted who would transition, enabling earlier referral and prevention efforts.

Read More
Innate, adaptive, and TNF-Superfamily immune pathways inform a lupus disease activity immune index that characterizes disease activity in SLE

This study developed a Lupus Disease Activity Immune Index integrating 32 soluble mediators weighted by autoantibody burden, successfully distinguishing active from low disease activity, correlating with SLEDAI scores, and identifying renal involvement to guide objective SLE management.

Read More
Ability of Innate, Adaptive, and TNF-Superfamily Immune Pathways to CharacterizeDisease Activity and Inform a Refined Lupus Disease Activity Immune in a Confirmatory Cohortof SLE Patients

This study refined a Lupus Disease Activity Immune Index using 12 prioritized soluble mediators and autoantibody breadth, significantly distinguishing low versus active SLE, correlating with hSLEDAI, and identifying renal involvement, supporting objective, treat-to-target disease monitoring in practice

Read More
A Refined Disease Activity Immune Index Informed by Select Immune Mediators That Characterizes Clinical Disease Activity in Systemic Lupus Erythematosus

This study refined a blood-based Lupus Disease Activity Immune Index using nine key soluble mediators and autoantibody breadth, accurately distinguishing active from low/quiescent SLE and correlating with hSLEDAI, supporting objective, treat-to-target monitoring in clinical practice.

Read More
Select Soluble Mediators Inform a Refined Lupus Disease Activity Immune Index that Characterizes Clinical Disease Activity in Systemic Lupus Erythematosus

This study refined a blood-based Lupus Disease Activity Immune Index(L-DAI) using 33 soluble mediators and autoantibody breadth with machine learning, accurately distinguishing active from low SLE activity and offering clinically actionable, objective augmentation to traditional scoring systems

Read More